Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing.

Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK.

Mol Carcinog. 2018 Oct 8. doi: 10.1002/mc.22919. [Epub ahead of print]

PMID:
30294913
2.

Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression.

Rogers TJ, Christenson JL, Greene LI, O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A, Degala GD, Shin J, Tan AC, Cittelly DM, Lambert JR, Richer JK.

Mol Cancer Res. 2018 Sep 13. doi: 10.1158/1541-7786.MCR-18-0246. [Epub ahead of print]

PMID:
30213797
3.

A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma.

Greene LI, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K, Borges VF, Slansky JE, Richer JK.

Mol Cancer Res. 2018 Aug 24. doi: 10.1158/1541-7786.MCR-18-0362. [Epub ahead of print]

PMID:
30143553
4.

Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.

Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK.

Horm Cancer. 2018 Apr;9(2):82-94. doi: 10.1007/s12672-017-0314-5. Epub 2018 Jan 16. Review.

PMID:
29340907
5.

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer.

He L, Du Z, Xiong X, Ma H, Zhu Z, Gao H, Cao J, Li T, Li H, Yang K, Chen G, Richer JK, Gu H.

Sci Rep. 2017 Nov 6;7(1):14584. doi: 10.1038/s41598-017-14607-2.

6.

The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.

Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM.

Horm Cancer. 2017 Dec;8(5-6):269-285. doi: 10.1007/s12672-017-0302-9. Epub 2017 Jul 24.

PMID:
28741260
7.

Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.

Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK.

Cancer Res. 2017 Jul 1;77(13):3455-3466. doi: 10.1158/0008-5472.CAN-16-3240. Epub 2017 May 16.

8.

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK.

Mol Cancer Ther. 2017 Jul;16(7):1389-1400. doi: 10.1158/1535-7163.MCT-17-0111. Epub 2017 May 3.

9.

MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.

Christenson JL, Butterfield KT, Spoelstra NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen BS, Katzenellenbogen JA, Richer JK.

Horm Cancer. 2017 Apr;8(2):69-77. doi: 10.1007/s12672-017-0285-6. Epub 2017 Feb 13.

10.

Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis.

Heinz RE, Rudolph MC, Ramanathan P, Spoelstra NS, Butterfield KT, Webb PG, Babbs BL, Gao H, Chen S, Gordon MA, Anderson SM, Neville MC, Gu H, Richer JK.

Development. 2016 Nov 15;143(22):4236-4248. Epub 2016 Oct 11.

11.

Cooperative Dynamics of AR and ER Activity in Breast Cancer.

D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK.

Mol Cancer Res. 2016 Nov;14(11):1054-1067. Epub 2016 Aug 26.

12.

Anti-androgen therapy in triple-negative breast cancer.

Barton VN, Gordon MA, Richer JK, Elias A.

Ther Adv Med Oncol. 2016 Jul;8(4):305-8. doi: 10.1177/1758834016646735. Epub 2016 May 31. No abstract available.

13.

Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison.

Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK.

Hum Pathol. 2016 Oct;56:40-51. doi: 10.1016/j.humpath.2016.05.014. Epub 2016 May 31.

14.

A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.

D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK.

Cancer Res. 2015 Nov 1;75(21):4651-64. doi: 10.1158/0008-5472.CAN-15-2011. Epub 2015 Sep 11.

15.

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.

Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK.

Horm Cancer. 2015 Dec;6(5-6):206-13. doi: 10.1007/s12672-015-0232-3. Epub 2015 Jul 23. Review.

PMID:
26201402
16.

Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.

Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK.

Mol Cancer Ther. 2015 Mar;14(3):769-78. doi: 10.1158/1535-7163.MCT-14-0926. Epub 2015 Feb 23.

17.

Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.

Niemeyer BF, Parrish JK, Spoelstra NS, Joyal T, Richer JK, Jedlicka P.

PLoS One. 2015 Jan 20;10(1):e0116895. doi: 10.1371/journal.pone.0116895. eCollection 2015. Erratum in: PLoS One. 2015;10(3):e0120830.

18.

Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.

Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA.

Oncogene. 2015 Jul;34(28):3676-87. doi: 10.1038/onc.2014.298. Epub 2014 Sep 22.

19.

Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b.

Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK.

Horm Cancer. 2014 Dec;5(6):374-89. doi: 10.1007/s12672-014-0188-8. Epub 2014 Sep 12.

20.

Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.

Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S.

Sci Transl Med. 2014 Mar 26;6(229):229ra41. doi: 10.1126/scitranslmed.3008326.

21.

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.

Breast Cancer Res. 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599.

22.

Glucose promotes breast cancer aggression and reduces metformin efficacy.

Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD.

Cell Cycle. 2013 Dec 15;12(24):3759-69. doi: 10.4161/cc.26641. Epub 2013 Oct 3.

23.

MicroRNA regulation of epithelial plasticity in cancer.

D'Amato NC, Howe EN, Richer JK.

Cancer Lett. 2013 Nov 28;341(1):46-55. doi: 10.1016/j.canlet.2012.11.054. Epub 2012 Dec 8. Review.

PMID:
23228634
24.

miR-200c targets a NF-κB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer.

Howe EN, Cochrane DR, Cittelly DM, Richer JK.

PLoS One. 2012;7(11):e49987. doi: 10.1371/journal.pone.0049987. Epub 2012 Nov 21.

25.

Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.

Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK.

Mol Cancer Ther. 2012 Dec;11(12):2556-65. doi: 10.1158/1535-7163.MCT-12-0463. Epub 2012 Oct 16.

26.

Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.

Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK.

Oncogene. 2013 May 16;32(20):2555-64. doi: 10.1038/onc.2012.275. Epub 2012 Jul 2.

27.

The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity.

Howe EN, Cochrane DR, Richer JK.

J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):65-77. doi: 10.1007/s10911-012-9244-6. Epub 2012 Feb 17. Review.

28.

Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer.

Cochrane DR, Jacobsen BM, Connaghan KD, Howe EN, Bain DL, Richer JK.

Mol Cell Endocrinol. 2012 May 15;355(1):15-24. doi: 10.1016/j.mce.2011.12.020. Epub 2012 Jan 18.

29.

The role of miRNAs in progesterone action.

Cochrane DR, Spoelstra NS, Richer JK.

Mol Cell Endocrinol. 2012 Jun 24;357(1-2):50-9. doi: 10.1016/j.mce.2011.09.022. Epub 2011 Sep 17. Review.

PMID:
21952083
30.

MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer.

Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK.

Horm Cancer. 2010 Dec;1(6):306-19. doi: 10.1007/s12672-010-0043-5.

31.

Targets of miR-200c mediate suppression of cell motility and anoikis resistance.

Howe EN, Cochrane DR, Richer JK.

Breast Cancer Res. 2011 Apr 18;13(2):R45. doi: 10.1186/bcr2867.

32.

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.

Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE.

Mol Cancer. 2010 Dec 20;9:317. doi: 10.1186/1476-4598-9-317.

33.

Steroid receptors and microRNAs: relationships revealed.

Cochrane DR, Cittelly DM, Richer JK.

Steroids. 2011 Jan;76(1-2):1-10. doi: 10.1016/j.steroids.2010.11.003. Epub 2010 Nov 18. Review.

PMID:
21093468
34.

Ovarian steroid hormones: what's hot in the stem cell pool?

Cittelly DM, Richer JK, Sartorius CA.

Breast Cancer Res. 2010;12(4):309. doi: 10.1186/bcr2627. Epub 2010 Aug 31.

35.

microRNAs and EMT in mammary cells and breast cancer.

Wright JA, Richer JK, Goodall GJ.

J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):213-23. doi: 10.1007/s10911-010-9183-z. Epub 2010 May 25. Review.

PMID:
20499142
36.

Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers.

Cochrane DR, Howe EN, Spoelstra NS, Richer JK.

J Oncol. 2010;2010:821717. doi: 10.1155/2010/821717. Epub 2009 Dec 15.

37.

MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents.

Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK.

Mol Cancer Ther. 2009 May;8(5):1055-66. doi: 10.1158/1535-7163.MCT-08-1046. Epub 2009 May 12.

38.

Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient.

Dimitrova IK, Richer JK, Rudolph MC, Spoelstra NS, Reno EM, Medina TM, Bradford AP.

Fertil Steril. 2009 Jun;91(6):2650-63. doi: 10.1016/j.fertnstert.2008.03.071. Epub 2008 Jul 30.

39.

ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.

Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK.

Mod Pathol. 2008 Jul;21(7):912-23. doi: 10.1038/modpathol.2008.82. Epub 2008 May 16.

40.

Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor.

Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB.

Breast Cancer Res Treat. 2008 Dec;112(3):489-501. doi: 10.1007/s10549-008-9923-6. Epub 2008 Mar 13.

PMID:
18338247
41.

Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.

Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK.

Breast Cancer Res Treat. 2008 Dec;112(3):475-88. doi: 10.1007/s10549-008-9897-4. Epub 2008 Mar 9.

PMID:
18327671
42.

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.

Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D.

Br J Cancer. 2006 Nov 6;95(9):1220-8. Epub 2006 Oct 17.

43.

Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers.

Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M.

Mod Pathol. 2006 Dec;19(12):1593-605. Epub 2006 Sep 15.

44.

Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B.

Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB.

Mol Endocrinol. 2006 Nov;20(11):2656-70. Epub 2006 Jun 8.

PMID:
16762974
45.

The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers.

Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, Broaddus RR, Horwitz KB, Richer JK.

Cancer Res. 2006 Apr 1;66(7):3893-902.

46.

Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture.

Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB.

Endocrinology. 2006 Feb;147(2):700-13. Epub 2005 Oct 20.

PMID:
16239301
47.

Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75.

Carvajal A, Espinoza N, Kato S, Pinto M, Sadarangani A, Monso C, Aranda E, Villalon M, Richer JK, Horwitz KB, Brosens JJ, Owen GI.

Breast Cancer Res Treat. 2005 Nov;94(2):171-83.

PMID:
16175315
48.

Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.

Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR.

J Steroid Biochem Mol Biol. 2005 Dec;97(4):328-41. Epub 2005 Sep 12.

PMID:
16157482
49.
50.

Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1.

Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Sadarangani A, Villalon M, Brosens JJ, White JO, Richer JK, Horwitz KB, Owen GI.

J Clin Endocrinol Metab. 2005 Feb;90(2):1181-8. Epub 2004 Nov 23.

PMID:
15562024

Supplemental Content

Loading ...
Support Center